SOMERVILLE, Mass., September 13, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has completed the restatement of its consolidated financial statements for the year ended December 31, 2022, and for each of the first three quarters of 2022 and 2023. Today, the Company filed its Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K"), including the restated information, and Form 10-Q for the quarter ended March 31, 2024 (the "Q1 2024 Form 10-Q") with
SOMERVILLE, Mass., August 28, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will participate in fireside chats at the following upcoming investor conferences: